Evidence map›Paper›PMID 36179015›Full record

ArticleJornal brasileiro de nefrologia

Preemptive kidney transplantation: why, when, and how?

Ana Flávia Moura, José A Moura-Neto, Lucio R Requião-Moura, Álvaro Pacheco-Silva

Abstract read
In one paragraph

Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ana Flávia MouraEscola Bahiana de Medicina e Saúde Pública, Departamento de Clínica Médica, Salvador, BA, Brasil.ORCID http://orcid.org/0000-0001-7368-4704
José A Moura-NetoEscola Bahiana de Medicina e Saúde Pública, Departamento de Clínica Médica, Salvador, BA, Brasil.ORCID http://orcid.org/0000-0003-1339-3731
Lucio R Requião-MouraUniversidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Medicina, Divisão de Nefrologia, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0001-8751-9048
Álvaro Pacheco-SilvaUniversidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Medicina, Divisão de Nefrologia, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0003-0293-976X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among renal replacement therapies, preemptive kidney transplantation (PKT) presents the best clinical, social, and economic results. However, it is still infrequently chosen as first therapy for patients with irreversible kidney failure. Initiatives in different parts of the world were developed to identify the reasons why PKT is still not widely used and to facilitate the access of patients with end-stage kidney disease to the advantages associated with it. This article addresses the main advantages and difficulties of PKT and discusses when it should be indicated and how to prepare potential recipients for PKT.

Indexed as

Kidney Failure, ChronicKidney TransplantationHumansRenal DialysisRenal Replacement Therapy

Identifiers

PMID36179015
PMCPMC10697151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.